Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Research In Brief

This article was originally published in The Gray Sheet

Executive Summary

Endologix percutaneous AAA study: Enrollment begins in firm's multi-center, prospective, randomized trial of the PowerLink stent graft in percutaneous endovascular abdominal aortic aneurysm repair (PEVAR), Endologix announces April 14. The study will enroll up to 150 subjects at 20 U.S. sites. All patients will be treated with PowerLink, delivered on Endologix' IntuiTrak system, but 100 will undergo PEVAR, while 50 will undergo standard endovascular AAA repair. Investigators also will use a "pre-close" technique on the PEVAR patients, facilitated by Abbott Vascular's ProStar XL percutaneous vascular surgical system or Perclose ProGlide suture-mediated closure system. PEVAR does not require an open surgical cut-down of the femoral arteries like standard EVAR, since access is achieved via a percutaneous approach. Endologix notes that there are no devices currently in clinical trials or approved by FDA for a PEVAR indication
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

MT028769

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel